These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19662218)

  • 1. Validation of candidate serum ovarian cancer biomarkers for early detection.
    Su F; Lang J; Kumar A; Ng C; Hsieh B; Suchard MA; Reddy ST; Farias-Eisner R
    Biomark Insights; 2007 Oct; 2():369-75. PubMed ID: 19662218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of serum biomarkers for detection of early stage ovarian cancer.
    Kozak KR; Su F; Whitelegge JP; Faull K; Reddy S; Farias-Eisner R
    Proteomics; 2005 Nov; 5(17):4589-96. PubMed ID: 16237736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of serum biomarkers for detection of early- and late-stage endometrial cancer.
    Farias-Eisner G; Su F; Robbins T; Kotlerman J; Reddy S; Farias-Eisner R
    Am J Obstet Gynecol; 2010 Jan; 202(1):73.e1-5. PubMed ID: 19766980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF].
    Zhao Q; Duan W; Wu YM; Qian XH; Deng XH
    Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):754-8. PubMed ID: 19173805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Value of Plasma Annexin A2 in Early-Stage High-Grade Serous Ovarian Cancer.
    Lokman NA; Ricciardelli C; Stephens AN; Jobling TW; Hoffmann P; Oehler MK
    Diagnostics (Basel); 2021 Jan; 11(1):. PubMed ID: 33406648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The proliferative activity of ovarian tumors of low malignant potential differs from that of ovarian carcinoma.
    Nakayama K; Takebayashi Y; Hata K; Fujiwaki R; Iida K; Fukumoto M; Miyazaki K
    Anticancer Res; 2003; 23(6C):4657-62. PubMed ID: 14981910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative.
    Dunton CJ; Hutchcraft ML; Bullock RG; Northrop LE; Ueland FR
    Diagnostics (Basel); 2021 Aug; 11(8):. PubMed ID: 34441373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of serum biomarkers for detection of early-stage ovarian cancer.
    Nosov V; Su F; Amneus M; Birrer M; Robins T; Kotlerman J; Reddy S; Farias-Eisner R
    Am J Obstet Gynecol; 2009 Jun; 200(6):639.e1-5. PubMed ID: 19285648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of HE4 and TTR for diagnosis of ovarian cancer: Comparison with CA-125.
    Zheng X; Chen S; Li L; Liu X; Liu X; Dai S; Zhang P; Lu H; Lin Z; Yu Y; Li G
    J Gynecol Obstet Hum Reprod; 2018 Jun; 47(6):227-230. PubMed ID: 29609043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
    PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucin 13 (MUC13) as a candidate biomarker for ovarian cancer detection: potential to complement CA125 in detecting non-serous subtypes.
    Ren AH; Filippou PS; Soosaipillai A; Dimitrakopoulos L; Korbakis D; Leung F; Kulasingam V; Bernardini MQ; Diamandis EP
    Clin Chem Lab Med; 2023 Feb; 61(3):464-472. PubMed ID: 36380677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Improved Prediction Model for Ovarian Cancer Using Urinary Biomarkers and a Novel Validation Strategy.
    Lee SW; Lee HY; Bang HJ; Song HJ; Kong SW; Kim YM
    Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31590408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and validation of differential plasma proteins levels in epithelial ovarian cancer.
    Periyasamy A; Gopisetty G; Subramanium MJ; Velusamy S; Rajkumar T
    J Proteomics; 2020 Aug; 226():103893. PubMed ID: 32634479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker.
    Lehtinen L; Vesterkvist P; Roering P; Korpela T; Hattara L; Kaipio K; Mpindi JP; Hynninen J; Auranen A; Davidson B; Haglund C; Iljin K; Grenman S; Siitari H; Carpen O
    PLoS One; 2016; 11(3):e0151590. PubMed ID: 26981633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
    Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Kjaerbye-Thygesen A; Gayther S; Jacobs IJ; Høgdall CK
    Gynecol Oncol; 2007 Mar; 104(3):508-15. PubMed ID: 17113137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
    Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
    Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer.
    Høgdall C; Fung ET; Christensen IJ; Nedergaard L; Engelholm SA; Petri AL; Risum S; Lundvall L; Yip C; Pedersen AT; Hartwell D; Lomas L; Høgdall EV
    Gynecol Oncol; 2011 Nov; 123(2):308-13. PubMed ID: 21855971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.
    Russell MR; Graham C; D'Amato A; Gentry-Maharaj A; Ryan A; Kalsi JK; Ainley C; Whetton AD; Menon U; Jacobs I; Graham RLJ
    Br J Cancer; 2017 Aug; 117(5):666-674. PubMed ID: 28664912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
    Dayyani F; Uhlig S; Colson B; Simon K; Rolny V; Morgenstern D; Schlumbrecht M
    Int J Gynecol Cancer; 2016 Nov; 26(9):1586-1593. PubMed ID: 27540691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.